Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

INTERIM REPORT, THIRD QUARTER OF 2017

July – September 2017The numbers refer to the remaining operations · Net sales for the period SEK 31.5 million (37.8) · Operating result for the period after nonrecurring items attributable to restructuring SEK -12 932 million · Operating loss for the period SEK -33.5 million (-10.8) · Loss after tax for the period SEK -63 million (-11) · Earnings per share SEK -1.07 (-0.20) · Cash flow before changes in working capital for the period SEK -40.7 million (-22.4) +-----------------------------------+-----+-----+--------+--------+---------+|Overview

New main owners in Actic

Athanase Industrial Partners has together with a number of new and existing institutional owners, from the listing earlier this year, acquired the remaining shareholding of 41.81 percent from Actic International S.à.r.l owned by the IK 2007 Fonden. The deal was made following the Nasdaq Stockholm Stock Exchange closing on Tuesday through a club deal led by SEB."By strengthening its offer and having the most cost effective structure, Actic can lead to the consolidation that takes place in the market. It will create significant value for both customers and shareholders. Therefore, Athanase

RhoVac AB announces that the first patient in the company’s clinical phase I/II study has now completed the treatment phase with cancer vaccine RV001

In April 2017, RhoVac AB ("RhoVac") announced that the treatment of the first patient in phase I/II clinical study was initiated. The company now announces that the same patient has completed the treatment phase on eleven doses of cancer vaccine RV001. RhoVac's CEO Anders Ljungqvist has provided more information about the status of the clinical study in this newsletter.On April 5th 2017, RhoVac announced that the first patient in phase I/II clinical study was treated with company's cancer vaccine, RV001. At the beginning of July 2017, it was announced that the patient recruitment for this

IRLAB receives MHRA approval to conduct Phase II trials with IRL790 in Britain

IRLAB has received approval from the Medicines & Healthcare products Regulatory Agency (MHRA) to conduct a Phase II study with the drug candidate IRL790 for treatment of L-dopa induced dyskinesias (LIDs). The study will be conducted at UK clinics.This Phase II clinical trial aims to study effect of IRL790 on dyskinesia in patients suffering from LIDs using UDysRS (the Unified Dyskinesia Rating Scale), the scale accepted by regulatory bodies. The 74 patients study will be conducted at several UK centres and is expected to be concluded in Q3 2018. The Phase II study is based on, and aims

SUMMARY OF INTERIM REPORT JULY-SEPTEMBER 2017

THE CURRENT PERIOD (3 months, July - September) · Net profit was KSEK -7,860 KSEK (400) · Result per share to SEK -0.07 (0.00) · The Group sale was KSEK 17 (0) · Net Investments were during the period 6,972 KSEK (2,656) · An updated Technical Report of the Silver Mine was completed in July that amongst other shows a Payback of less than two years from start of production · The Board decided to move the Blaiken plant to Sotkamo, Finland · On going discussions with Traxys but also with other potential financiers, an increased interest have been proven after the release

Sale of shares in Actic Group AB to nine high quality investors including Athanase Industrial Partner

Actic International S.à.r.l. (a holding company owned by the IK 2007 Fund) has entered into an agreement to sell 6,647,078 shares in Actic Group AB (publ) ("Actic") to nine high quality Swedish investors, including Athanase Industrial Partner (“Athanase”).Athanase, Cornerstone investor in the listing of Actic, will through the transaction increase its holding in Actic from approximately 7.9% to 15.4% of the total number of shares outstanding. After the sale, the IK 2007 Fund, advised by IK Investment Partners, no longer owns any shares in Actic. SEB acted as Sole Bookrunner in the

TORM files for US Nasdaq listing

TORM plc plans to file a registration statement with the U.S. Securities and Exchange Commission later today in connection with its direct share listing on the Nasdaq Stock Market in New York, which TORM expects to complete before the end of 2017. Following the listing, TORM's Class A common shares will be listed for trading on both Nasdaq Copenhagen under the symbol "TRMD A" and Nasdaq New York under the symbol "TRMD". The purpose of a dual listing is to provide our investors with the ability to trade their Class A common shares on a USD-denominated exchange and to improve the

Interim Report January - September 2017 Storytel AB (publ)

See video here  with CEO Jonas Tellander and CFO Sofie Zettergren commenting Q3 2017 Summary of Q3, 2017 Highlights from the past quarter (compared to  Q3, 2016) ·Increased subscription base from 423,200 to 503,900 subscribers (341,500) ·Increased Streaming-revenue from 167.0 MSEK to 197.9 MSEK (135.7 MSEK) ·Increased share of international Streaming-revenue from 39.3% to 42.5% (36.0%) ·Issued new shares worth 200 MSEK to the company. ·Prepared to launch service in Spain; started Spanish service after close

NeuroVive presents TBI clinical study results at Nordic Neurotrauma Conference

Lund, Sweden, 15 November 2017 – NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company will present data from its clinical phase IIa study on traumatic brain injury (TBI), Copenhagen Head Injury Ciclosporin Study (CHIC), at the Nordic Neurotrauma Conference (NNC) in Lund, Sweden. The results will be presented at the NNC today by the study’s Principal Investigator, Dr. Jesper Kelsen at the Department of Neurosurgery at Rigshospitalet in Copenhagen, Denmark.The study, which includes evaluation of pharmacokinetic parameters and safety in a TBI-

100th anniversary donation by the Knut and Alice Wallenberg Foundation: SEK 1.6 billion for artificial intelligence and quantum technology research

With developments in quantum technology and artificial intelligence (AI) predicted to have a major impact on research activities and society at large, the Knut and Alice Wallenberg Foundation (KAW) has decided to award grants amounting to SEK 1.6 billion over the coming decade for research into these two key technological fields of the future.“A constant aim throughout the 100-year history of the Foundation has been to fund basic research to drive the development of innovative technology that will contribute to Sweden’s long-term progress as a pioneering and industrial nation,” says Peter

Interim financial report - Q1-Q3 2017

Company announcement No: 352 H+H International A/SLautrupsgade 7, 6th. Floor2100 Copenhagen ØDenmarkTel.: +45 35 27 02 00www.HplusH.comCompany reg. no. 49 61 98 12LEI 213800GJODT6FV8QM841 Highlights for the period 1 January to 30 September 2017 · Revenue for the third quarter remained stable in local currencies and decreased by 2% in DKK to DKK 430 million (2016: DKK 439 million). Revenue for the first three quarters increased by 2% in local currencies and decreased by 1% in DKK to DKK 1,252 million (2016: DKK 1,264 million). · EBITDA before special items for

Avanza launches Sweden’s lowest mortgage rate with no savings requirement

Avanza is offering a mortgage with an interest rate of 1.29 per cent – by far the lowest average rate with no savings requirement. The offer will initially target a select group of customers before it is expanded to the general public early next year. The mortgage is for customers with a loan to value ratio of no higher than 60 per cent, which applies to more than half of Sweden’s total mortgage volume.The offer is built on a model with a mortgage fund, which pension providers and other institutional investors will have the opportunity to invest in. This will mean a less expensive mortgage,

TORM plc interim results for the third quarter of 2017

"During the third quarter of 2017, TORM achieved competitive blended freight rates of USD/day 14,290, a satisfactory result considering that the freight market in general was weak for most of the quarter. Towards the end of the quarter, the market was affected by the hurricane Harvey and refinery disruptions in Mexico which briefly lifted Atlantic MR rates and had an even more sustained effect on Far East MR rates with increasing transport distances towards the Americas. The disruption to the refinery system at the US Gulf Coast has accelerated the draws on inventories in the western

Finnair starts flight ticket sales directly via WeChat in China as the first European airline, enables payments with WeChat Pay

Finnair is launching flight ticket sales directly via its official WeChat account in China as the first European airline. It is now also possible to use WeChat Pay as a payment method for the flight tickets sold through its official WeChat account. Finnair customers are now able to search for Finnair flight tickets, book their flights and complete their purchase with WeChat Pay, all directly through Finnair's official WeChat account. This enhances the user experience as customers stay within the same platform throughout the entire booking process. “China is one of our most

Raisio's converted shares

Raisio plc      Stock Exchange Release, 15 November 2017 RAISIO'S CONVERTED SHARES The Board of Directors of Raisio plc has decided in its meeting held on 2 November 2017 to convert a total of 86,961 restricted shares (series K) into free shares (series V). The decision has been entered in the Trade Register today, on 15 November 2017. The additional lot of free shares in question is admitted to trading on the Nasdaq Helsinki Ltd as of 16 November 2017. Since the beginning of 2017, a total of 139,577 restricted shares of the company have been converted into free shares. The number

Ahlsell acquires work-protection wholesaler in the Värmland-region

Ahlsell Sverige AB has signed an agreement to acquire the operations of Gehås AB with annual sales of approximately MSEK 15. Gehås sells work-protection clothes, profile products, stationery and office supplies in Värmland, Sweden, and has two stores; one in Arvika and one in Årjäng. The stores sell mostly well-known branded goods within workwear and clothing. The company is privately owned and has six employees. Customers are mainly corporates and municipalities. "The acquisition of the Gehås operations will further strengthen our presence in Värmland within personal protective

Bonava acquires land and creates neighbourhood with about 350 housing units in Botkyrka

Bonava has signed an agreement to acquire a property from Stenhus Förvaltning Stockholm. The property is located in central Tumba in Botkyrka municipality, an area where Bonava plans to construct about 350 housing units.The property is part of the Samariten block and has been identified as a prioritised development area in Botkyrka, given its attractive location north of central Tumba. The area is located close to schools, service and public transport, with good connections to the centre of Stockholm. - I’m pleased to be expanding our project and development rights portfolio in a growing

ASTRAZENECA PLC ANNOUNCES FASENRA (BENRALIZUMAB) RECEIVES US FDA APPROVAL FOR SEVERE EOSINOPHILIC ASTHMA

Fasenra distinctively targets and rapidly depletes eosinophils and is the first respiratory biologic with an 8-week maintenance dosing scheduleThis announcement contains inside information   14 November 2017 22:45 GMT    FDA approval based on Phase III programme demonstrating up to 51% reduction in asthma exacerbations, significant improvement in lung function and a 75% reduction in daily oral steroid use     AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has approved Fasenra (

Clavister recruits Chief Strategy Officer from IBM and Google

The appointment of a senior Chief Strategy Officer adds an important component to Clavister’s business plan and growth ambitions.November 15th, 2017, Örnsköldsvik, Sweden - Clavister, a leader in high-performance network security solutions, today announced the addition of Przemek Sienkiewicz as the new Chief Strategy Officer to the executive management team, effective immediately.  Sienkiewicz, a seasoned professional with experience from IBM where he has been their director for cloud and cognitive business—as well as creating and heading up Google’s enterprise business in some 30

Oncopeptides AB Interim Report July - September 2017

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the third quarter 2017 report. “The data from our study, O-12-M1, provides us with an increased degree of comfort regarding a positive clinical outcome in our pivotal study OCEAN” SUMMARY OF Q3 July 1st – September 30th 2017 Significant events after the period · Net sales amounted to 0.0 (0.0) July 1st to September 30th 2017MSEK · On November 1st, we announced that · Loss for the period was 51.6 we will present results from two(loss: 24.7) MSEK

Schörling & Partners AB publishes offer document

The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the United States of America, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law.On 14 November

Fortum's Shareholders' Nomination Board confirms Board of Directors' ability to function

FORTUM CORPORATION STOCK EXCHANGE RELEASE 15 NOVEMBER 2017 AT 9:00 EETFortum's Shareholders' Nomination Board has evaluated the Board of Directors'ability to function, following the unfortunate passing of Tapio Kuula, memberof the Board of Directors.The Shareholders' Nomination Board, based on the recommendation of the Board ofDirectors, considers the Board of Directors to be able to function in itscurrent composition until the Annual General Meeting planned to be held on 28March 2018.Fortum CorporationMåns HolmbergActing head of Investor Relations & Financial

Lehto Group Plc: Managers' Transactions

Lehto Group PlcManagers' Transactions15th November 2017 at 8:40 am    Lehto Group Plc - Managers' Transactions__________________________________________ Person subject to the notification requirement Name: Myllymäki, Asko Position: Other senior manager (X) Legal person Issuer: Lehto Group Oyj LEI: 743700YEHY9I3ZDHNX66   Notification type: INITIAL NOTIFICATION Reference number: 743700YEHY9I3ZDHNX66_20171115080748_5 ____________________________________________ Transaction date: 2017-11-13 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type:

There are no items matching the current filter
There are no more items matching the current filter
Back to top